@Jinxthejjinx@ChadDKollas@OregonAdvocate@PainMedJournal@LabGirl_Chloe@supportprop 1/I see this paper as direct, and not one that is terribly supportive of tapering policies (and it's good to report this): it's clear from this report that taper often fails, and that switch to buprenorphine helps some, and at least as often fails with others.
@Jinxthejjinx@ChadDKollas@OregonAdvocate@PainMedJournal@LabGirl_Chloe@supportprop 3/Here it says that among the subset of 89 who got all the way below 90 MME, the majority (52%) had ⬆️ of pain, but 24% had no change and 24% had ⬇️ of pain. This means that taper may help some pain, but more often it does the opposite. That's the data.
@Jinxthejjinx@ChadDKollas@OregonAdvocate@PainMedJournal@LabGirl_Chloe@supportprop 4/There was a group that switched to buprenorphine. Please note, I personally have patients where that switch was helpful, and others who needed to go back. This paper finds that among 43 who switched, 18 had ⬆️pain, 4 had no change, and 21 had ⬇️pain.
@Jinxthejjinx@ChadDKollas@OregonAdvocate@PainMedJournal@LabGirl_Chloe@supportprop 5/Here's my take: the authors "believe" in the program they offer. They assert (in the discussion, which is where authors do speculate) that what they did resulted in safety and prevented redistribution of medication in the community.
They have no evidence for those speculations
@Jinxthejjinx@ChadDKollas@OregonAdvocate@PainMedJournal@LabGirl_Chloe@supportprop 6/This study and others show us that policies to broadly incentivize opioid dose ⬇️on high-dose patients are not justifiable, but certainly an attempt at taper is something patients may seek to choose. Such findings are:
a)some feel better
b)others feel worse
No panacea
@Jinxthejjinx@ChadDKollas@OregonAdvocate@PainMedJournal@LabGirl_Chloe@supportprop 8/I want to separate research from advocacy here. From the start, as soon as I saw some patients harmed , I began advocating. Injuries to patients are ethically unacceptable. But even there I stick to what I see, and what evidence can show. Stick to truth, always.
@Jinxthejjinx@ChadDKollas@OregonAdvocate@PainMedJournal@LabGirl_Chloe@supportprop 9/The blowback I faced, just sticking to the facts and the science as I know it, was fierce & a bit scary. One day we can explore that, but not now. The next crucial step is to learn more, so we can speak with more clarity about what is happening to patients and families, now
• • •
Missing some Tweet in this thread? You can try to
force a refresh
🧵1/Our @uabmedicine Grand Rounds will feature a diagnostic showdown between Dr Martin Rodriguez and ChatGPT4
I am scared here because I don’t want AI to win
2/the case features behavioral changes, swearing, cognitive decline, cough, progressive weakness over 3 years.
I wonder about infectious and rheumatic disorders. Maybe primary neurological
Aspirations after a cognitive change is possible
Dr Rodriguez opens. Not much to go on.
3/ChatGPT generated a lot of text read by Dr Kraemer but it is pretty good, with emphasis on neurological disorders followed by a disclaimer “please note that this does not substitute for professional medical advice”. Both want more information
Truth💣 1/ The “NARXCare” opioid Rx risk algorithm is in all Prescription Monitoring Databases,ie ~1 bn Rx’s/year
NOW in @JournalGIM
✅evidence does not yet exist to support it as safe or protective
✅It has flourished due to lack of federal oversight link.springer.com/article/10.100…
2/The authors, led by Dr Michele Buonara, review the core argument as one in which this algorithm with low evidence to its favor
and high risk of harm
has gone unregulated
despite apparently fulfilling @US_FDA criteria that mandate it be regulated
3/Nearly all prescribers and national pharmacies now see the Bamboo Health, Inc proprietary “NARXcare” algorithm in a more prominent position *than the prescription history itself” when they view a prescription history.
1/Arguing for methadone deregulation, Dr. Ruth Potee notes that in an auditorium of 400 addiction specialists, almost NONE prescribe methadone (because they can't)
"Methadone is a miracle drug that no one has access to"
There are more people who offer Botox than offer methadone
Patient: “I can still do my activities”.
Doc: "No way, not really. I read the SPACE trial, and there is NO benefit (that would outweigh the opioids’ risk)”
"Shared decision-making" seems *doomed* here
1/I watch with concern as DEA prosecutions of MDs still seem to rely on “they prescribed more than I would” despite a 9-0 ruling of
Supreme Court last year
Sudden termination of opioids & progressive abandonment of 5-8 million patients is dangerous
1/Even on inpatient rounds, it is possible to introduce the idea that addiction isn’t (only) in the brain.
I contrast @NIAAAnews “brain disease” against a behavioral economics vide substance use as a pattern of behavior occurring in relation to environmental context
2/On teaching rounds we read aloud and discussed the @NIAAAnews brain-science model of addiction, pulling just a few lines off their website
3/then we read lines from Chapter 39 of “Evaluating the Brain Disease Model of Addiction” - this presents harmful substance use as a pattern of behavior based on assessment of competing rewards, delay or uncertainty of desired rewards, risks and costs - ie behavioral economics